AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14739732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study 11195235 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort) 500 microg bid
Number of subjects: 30
Study 11195235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11195235 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (Pulmicort)
Number of subjects: 30
Study 9104516 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.10% and 1 mg.ml‐1 meperidine (0.10% group)
Number of subjects: 60
Study 9104516 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.05% and 1 mg.ml‐1 meperidine (0.05% group)
Number of subjects: 60
Study 9104516 — intervention group
Group type: COMPARATOR
Intervention: 1 mg.ml‐1 meperidine (0% group)
Number of subjects: 60
Study 8026249 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg erythromycin
Number of subjects: 35
Study 8026249 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg erythromycin
Number of subjects: 35
Study 8026249 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1 mg/kg)
Number of subjects: 35
Study 8026249 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg/kg)
Number of subjects: 35
Study 2784233 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 250 ppm fluoride
Number of subjects: 1161
Study 2784233 — intervention group
Group type: COMPARATOR
Intervention: 1000 ppm sodium fluoride and MFP formulations
Number of subjects: 1161
Study 2784233 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticalculus agents (HEBP and AHBP)
Number of subjects: 1161
Study 1055858 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniospinal irradiation or cranial irradiation combined with intrathecal methotrexate
Number of subjects: 45
Study 1055858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic craniospinal irradiation
Number of subjects: 45
Study 1055858 — intervention group
Group type: COMPARATOR
Intervention: Control group (irradiation to parts of the body other than the cranium)
Number of subjects: 45
Study 1055858 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving prophylactic craniospinal irradiation)
Number of subjects: 45
Study 31508924 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFU hemi-ablation and concomitant short-term androgen deprivation therapy (ADT)
Number of subjects: 20
Study 28370340 — intervention group
Group type: EXPERIMENTAL
Intervention: P2B001 (0.6 mg pramipexole/0.75 mg rasagiline)
Number of subjects: 149
Study 28370340 — intervention group
Group type: EXPERIMENTAL
Intervention: P2B001 (0.3 mg pramipexole/0.75 mg rasagiline)
Number of subjects: 149
Study 28370340 — intervention group
Group type: EXPERIMENTAL
Intervention: Responder analysis for P2B001 (0.6/0.75 mg)
Number of subjects: 149
Study 28370340 — intervention group
Group type: EXPERIMENTAL
Intervention: Responder analysis for P2B001 (0.3/0.75 mg)
Number of subjects: 149
Study 28370340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 25939584 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended stroke rehabilitation service for 18 months following completion of ESD.
Number of subjects: 510
Study 25939584 — intervention group
Group type: COMPARATOR
Intervention: Usual stroke care post-ESD (control group).
Number of subjects: 510
Study 24671750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 13
Study 24671750 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 13
Study 22962411 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme iron polypeptide (HIP)
Number of subjects: 62
Study 22962411 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulphate
Number of subjects: 62
Study 19574871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular block (SCB)
Number of subjects: 120
Study 19574871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infraclavicular block (ICB)
Number of subjects: 120
Study 19574871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary block (AXB)
Number of subjects: 120
Study 17637268 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV + LAM (10 mg/d ADV and 100 mg/d LAM for 12 weeks, followed by 10 mg/d ADV for 36 weeks)
Number of subjects: 226
Study 17637268 — intervention group
Group type: COMPARATOR
Intervention: Placebo + LAM (placebo and 100 mg/d LAM for 12 weeks, followed by 10 mg/d ADV for 36 weeks)
Number of subjects: 226
Study 17637268 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV + LAM
Number of subjects: 226
Study 17637268 — intervention group
Group type: COMPARATOR
Intervention: Placebo + LAM
Number of subjects: 226
Study 17637268 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms after 36 weeks of therapy
Number of subjects: 226
Study 15275698 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MLT)
Number of subjects: 25
Study 15275698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12680528 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid meal (175 kcal)
Number of subjects: 18
Study 12680528 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid meal (375 kcal)
Number of subjects: 18
Study 12680528 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisolid meal
Number of subjects: 18
Study 12680528 — intervention group
Group type: COMPARATOR
Intervention: Liquid meal
Number of subjects: 18
Study 9830787 — intervention group
Group type: EXPERIMENTAL
Intervention: High daily dose of angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 9830787 — intervention group
Group type: COMPARATOR
Intervention: Low daily dose of angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 7793222 — intervention group
Group type: EXPERIMENTAL
Intervention: heterologous erythrocyte concentrate (group I)
Number of subjects: 45
Study 7793222 — intervention group
Group type: EXPERIMENTAL
Intervention: intra- and postoperative autotransfusion of blood salvaged with cellsaver technique (group II)
Number of subjects: 45
Study 7793222 — intervention group
Group type: EXPERIMENTAL
Intervention: predonated autologous erythrocyte concentrates together with salvaged blood (group III)
Number of subjects: 45
Study 7793222 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonoclot coagulation analyses
Number of subjects: 45
Study 2292532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 200 mg bd
Number of subjects: 251
Study 2292532 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav 500 mg/125 mg tds
Number of subjects: 251
Study 2292532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil
Number of subjects: 251
Study 6898629 — intervention group
Group type: EXPERIMENTAL
Intervention: Self Instructional Unit (SIU) on nursing care plans
Number of subjects: 48
Study 6898629 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Text Type (QTT)
Number of subjects: 48
Study 6898629 — intervention group
Group type: COMPARATOR
Intervention: Information Text Type (ITT)
Number of subjects: 48
Study 31777204 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback
Number of subjects: 1089
Study 31777204 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized feedback
Number of subjects: 1089
Study 28913671 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program based on PRECEDE model
Number of subjects: 300
Study 28913671 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 300
Study 27353505 — intervention group
Group type: EXPERIMENTAL
Intervention: blisibimod (200 mg QW)
Number of subjects: 547
Study 27353505 — intervention group
Group type: COMPARATOR
Intervention: blisibimod (placebo)
Number of subjects: 547
Study 27353505 — intervention group
Group type: EXPERIMENTAL
Intervention: blisibimod
Number of subjects: 547
Study 25944629 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill strategy
Number of subjects: 94
Study 23384944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive function assessed using Hodkinson Abbreviated Mental Test (AMT) at baseline and 18 months follow-up.
Number of subjects: 611
Study 23384944 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA class IV patients compared to NYHA II patients.
Number of subjects: 611
Study 23384944 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of SCI related to mortality.
Number of subjects: 611
Study 23384944 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in HF severity.
Number of subjects: 611
Study 21459499 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth ball exercise programme (26-page booklet and 19-minute videotape, practiced at home for at least 20 minutes three times a week for 6-8 weeks)
Number of subjects: 188
Study 21459499 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing and midwifery care (Control group)
Number of subjects: 188
Study 19892282 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 60
Study 19892282 — intervention group
Group type: COMPARATOR
Intervention: Placebo (laser probe positioned without actual laser intervention)
Number of subjects: 60
Study 19892282 — intervention group
Group type: COMPARATOR
Intervention: Control (no laser intervention)
Number of subjects: 60
Study 17044770 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato drink (250 ml)
Number of subjects: 20
Study 17044770 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 20
Study 12772138 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 42
Study 12772138 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 1:200,000 and bicarbonate
Number of subjects: 42
Study 12772138 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 42
Study 12772138 — intervention group
Group type: COMPARATOR
Intervention: Control group (lidocaine group)
Number of subjects: 42
Study 10702463 — intervention group
Group type: EXPERIMENTAL
Intervention: RAB-RAB (rabeprazole-rabeprazole)
Number of subjects: 180
Study 10702463 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA-RAN (placebo-ranitidine)
Number of subjects: 180
Study 10702463 — intervention group
Group type: EXPERIMENTAL
Intervention: LAN-LAN (lansoprazole-lansoprazole)
Number of subjects: 180
Study 10702463 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA-RAB (placebo-rabeprazole)
Number of subjects: 180
Study 10702463 — intervention group
Group type: EXPERIMENTAL
Intervention: RAB-PLA (rabeprazole-placebo)
Number of subjects: 180
Study 10702463 — intervention group
Group type: COMPARATOR
Intervention: PLA-PLA (placebo-placebo)
Number of subjects: 180
Study 2060566 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (50 mg/m2 as an iv bolus) administered at 21.00 h
Number of subjects: 18
Study 2060566 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (50 mg/m2 as an iv bolus) administered at 09.00 h
Number of subjects: 18
Study 6340496 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (2 mg/kg bolus, then 0.5 mg/kg per hour for 24 hours)
Number of subjects: 20
Study 6340496 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study 30876402 — intervention group
Group type: EXPERIMENTAL
Intervention: Female interviewers
Number of subjects: 965
Study 30876402 — intervention group
Group type: COMPARATOR
Intervention: Not accounting for interviewer identity in regressions
Number of subjects: 965
Study 30124724 — intervention group
Group type: EXPERIMENTAL
Intervention: Halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion
Number of subjects: 418
Study 30124724 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 418
Study 26487000 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection (SR)
Number of subjects: 1009
Study 26487000 — intervention group
Group type: COMPARATOR
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 1009
Study 25127210 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 40
Study 25127210 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline 0.9%
Number of subjects: 40
Study 23118981 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 115
Study 23118981 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercise
Number of subjects: 115
Study 20347511 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate, 70 mg, administered weekly (n = 25)
Number of subjects: 51
Study 20347511 — intervention group
Group type: COMPARATOR
Intervention: Placebo, matching (n = 25)
Number of subjects: 51
Study 18585542 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine orally disintegrating tablet (OLZ‐ODT)
Number of subjects: 87
Study 18585542 — intervention group
Group type: COMPARATOR
Intervention: Risperidone oral solution (RIS‐OS)
Number of subjects: 87
Study 16048422 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation training
Number of subjects: 17
Study 16048422 — intervention group
Group type: COMPARATOR
Intervention: Subjects without injuries (control group)
Number of subjects: 17
Study 12453852 — intervention group
Group type: EXPERIMENTAL
Intervention: vinorelbine-cisplatin (NP; vinorelbine 30 mg/m(2) on days 1, 8 and 15 with cisplatin 80 mg/m(2) on day 1)
Number of subjects: 259
Study 12453852 — intervention group
Group type: COMPARATOR
Intervention: vinorelbine-ifosfamide-cisplatin (NIP; vinorelbine 25 mg/m(2) on days 1 and 8, ifosfamide 3 g/m(2) on day 1 and cisplatin 75 mg/m(2) on day 1)
Number of subjects: 259
Study 10325913 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms/day budesonide
Number of subjects: 31
Study 10325913 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms/day budesonide
Number of subjects: 31
Study 10325913 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 micrograms/day budesonide
Number of subjects: 31
Study 10325913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8953661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 0
Study 8953661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1710483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural mitoxantrone
Number of subjects: 103
Study 1710483 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pleural tube alone with instillation of isotonic NaCl)
Number of subjects: 103
Study 6725040 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiosensitizing drug in radiotherapy
Number of subjects: 0
Study 6725040 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30184133 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (4 μg/kg)
Number of subjects: 23
Study 30184133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 29790614 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment (Lactobacillus rhamnosus and Enterococcus faecium)
Number of subjects: 34
Study 29790614 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 34
Study 27044933 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT + bevacizumab
Number of subjects: 102
Study 27044933 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 102
Study 24183908 — intervention group
Group type: COMPARATOR
Intervention: Epidural catheter (Group A)
Number of subjects: 52
Study 24183908 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral catheter (Group B)
Number of subjects: 52
Study 24032706 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous heparin infusion (8 U/kg/hr progressing to 10 U/kg/hr over 36 hours) starting 12 hours after surgery until Day 14
Number of subjects: 86
Study 24032706 — intervention group
Group type: COMPARATOR
Intervention: Conventional subcutaneous heparin twice daily as deep vein thrombosis prophylaxis
Number of subjects: 86
Study 20205099 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT(4)) treatment for one year
Number of subjects: 21
Study 20205099 — intervention group
Group type: COMPARATOR
Intervention: Iodine treatment only (Control)
Number of subjects: 21
Study 18788565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 69
Study 18788565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape obturator (TVT-O)
Number of subjects: 69
Study 18788565 — intervention group
Group type: COMPARATOR
Intervention: Both TVT and TVT-O
Number of subjects: 69
Study 16490423 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 1450
Study 16490423 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1450
Study 14711190 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day atorvastatin for 3 months
Number of subjects: 24
Study 14711190 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day atorvastatin for 3 months
Number of subjects: 24
Study 10781354 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy in community hospitals (group A)
Number of subjects: 300
Study 10781354 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy during transportation to angioplasty (group B)
Number of subjects: 300
Study 10781354 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate transportation for primary angioplasty without pre-treatment with thrombolysis (group C)
Number of subjects: 300
Study 10781354 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate transportation for primary angioplasty (group C)
Number of subjects: 300
Study 8890313 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental task involving identification of left or right hand presented in different orientations; subjects mentally moved their arm to match the experimenter's arm position.
Number of subjects: 0
Study 8890313 — intervention group
Group type: COMPARATOR
Intervention: Control condition with tactual stimulation without mental transformations.
Number of subjects: 0
Study 2056455 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate rinsing (15 ml b.i.d.)
Number of subjects: 30
Study 2056455 — intervention group
Group type: COMPARATOR
Intervention: Tap water rinsing (15 ml b.i.d.)
Number of subjects: 30
Study 6352046 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed-release dihydroergotamine preparation 10 mg/per os/day
Number of subjects: 90
Study 6352046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 30992295 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week antibiotic therapy
Number of subjects: 154
Study 30992295 — intervention group
Group type: COMPARATOR
Intervention: 4-week antibiotic therapy
Number of subjects: 154
Study 28976056 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 50
Study 28976056 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 50
Study 27270237 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg sc every 6 months
Number of subjects: 643
Study 27270237 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic Acid 5 mg iv once
Number of subjects: 643
Study 24570297 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Monitoring and Optimization (MeMO) intervention, comprising continuous monitoring and tailored counseling sessions, N = 495
Number of subjects: 937
Study 24570297 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmacy care, N = 442
Number of subjects: 937
Study 22050030 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (0, 12, 50 mg/70 kg)
Number of subjects: 13
Study 22050030 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (0, 12, 50 mg/70 kg)
Number of subjects: 13
Study 22050030 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine
Number of subjects: 13
Study 22050030 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 13
Study 22050030 — intervention group
Group type: COMPARATOR
Intervention: Methamphetamine and d-amphetamine
Number of subjects: 13
Study 21037194 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home technique with 10% carbamide peroxide
Number of subjects: 17
Study 21037194 — intervention group
Group type: COMPARATOR
Intervention: In-office technique with 38% hydrogen peroxide
Number of subjects: 17
Study 17624482 — intervention group
Group type: EXPERIMENTAL
Intervention: Network-based rehabilitation intervention (3 in-patient periods totaling 21 days and a home visit by a professional)
Number of subjects: 741
Study 17624482 — intervention group
Group type: COMPARATOR
Intervention: Standard social and health services (control group)
Number of subjects: 741
Study 16316364 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-iterative method without urea rebound measurement (BUN3)
Number of subjects: 98
Study 16316364 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative method with BUN3
Number of subjects: 98
Study 16316364 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation formula of Daugirdas (when BUN3 is available)
Number of subjects: 98
Study 16316364 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate equation of Daugirdas and Schneditz (when BUN3 is not available)
Number of subjects: 98
Study 16316364 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of mKt/V and eKt/V
Number of subjects: 98
Study 11958805 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg body mass) given 1 h after exercise
Number of subjects: 19
Study 11958805 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-free solution administered 1 h after exercise
Number of subjects: 19
Study 16256705 — intervention group
Group type: EXPERIMENTAL
Intervention: R(+)‐ and S(‐)‐thioctic acid (TA) enantiomers administered orally and intravenously at a single dose of 200 mg rac‐TA.
Number of subjects: 22
Study 16256705 — intervention group
Group type: EXPERIMENTAL
Intervention: R(+)‐ and S(‐)‐thioctic acid (TA) enantiomers in patients with normal gastric emptying (group A, n=11).
Number of subjects: 22
Study 16256705 — intervention group
Group type: EXPERIMENTAL
Intervention: R(+)‐ and S(‐)‐thioctic acid (TA) enantiomers in patients with delayed gastric emptying (group B, n=11).
Number of subjects: 22
Study 16256705 — intervention group
Group type: EXPERIMENTAL
Intervention: R(+)‐ and S(‐)‐thioctic acid (TA) enantiomers in patients with delayed GET.
Number of subjects: 22